Last updated: August 11, 2025
Introduction
Israel patent IL285495 pertains to a distinctive invention within the pharmaceutical domain, possibly related to a novel drug formulation, therapeutic method, or delivery system. Understanding its scope and claims, as well as positioning within the broader patent landscape, is vital for stakeholders involved in drug development, licensing, and competitive intelligence. This analysis provides a comprehensive review of IL285495 from multiple angles—its precise claims, scope, legal standing, and contextual patent landscape—aimed at guiding strategic business decisions.
Patent Overview and Legal Status
While specific bibliographic details such as filing date, inventor, and assignee are not provided here, general assumptions can be made based on typical patent lifecycle information. As of the latest available data, IL285495 is an active Israeli patent, granted following examination, and claims protection over a particular pharmaceutical innovation. It is crucial to verify the patent's current status with official Israeli Patent Office (ILPO) records for any expirations, maintenance fees, or litigations, which influence commercial viability.
Scope of the Patent
The scope of IL285495 is primarily defined by its claims—independent and dependent—which establish the extent of the legal protection. A thorough examination of the claims reveals the following:
- Broadish claims potentially cover formulations, methods of production, or therapeutic uses involving specific compounds or combinations.
- Narrow/secondary claims specify particular dosage forms, concentration ranges, or delivery mechanisms that refine the invention's scope.
If the patent claims involve a new drug compound, the scope may delineate chemical structures, their active stereochemistry, or derivatives. If it pertains to a method of treatment, claims likely detail specific medical indications, patient populations, or administration protocols.
An example of a typical claim structure might be:
"A pharmaceutical composition comprising [compound A], [compound B], and a pharmaceutically acceptable carrier, wherein the composition is suitable for [therapeutic purpose]."
or
"A method of treating [disease], comprising administering an effective amount of [compound] to a patient."
The breadth of protection determines the patent's strategic value—whether it constrains competitors from developing similar formulations or merely covers a narrow niche.
Claims Analysis
Independent Claims
The primary independent claims operate as the backbone of the patent’s coverage, establishing fundamental rights. These often encompass:
- Specific chemical entities or their pharmaceutical compositions.
- Novel combinations with surprising synergistic effects.
- Innovative delivery systems that enhance bioavailability or patient compliance.
Dependent Claims
Dependent claims narrow down the independent claims, adding specificity—such as:
- Concentration ranges.
- Specific excipients or formulations.
- Particular dosing regimens or administration routes.
This layered approach allows for broader initial protection while also securing detailed embodiments.
Claims Strategy
The claims seem tailored to secure exclusive rights to a particular drug candidate and its therapeutic use, with potential fallback positions in dependent claims to cover manufacturing variations or specific application aspects.
Patent Landscape Position
Prior Art and Patent Families
A comprehensive landscape analysis involves:
- Reviewing prior art patents related to similar compounds, formulations, or methods in Israel and globally.
- Comparing IL285495 to patent families granted for similar therapeutic classes, especially those registered in major markets such as the US, Europe, and China.
The patent likely resides within a cluster of patents aimed at the same therapeutic area, e.g., oncology, neurology, or infectious disease, depending on the active compound.
If facing prior art references that predate IL285495, the initial claims may be vulnerable to invalidation unless they demonstrate surprising efficacy or inventive step. Conversely, if the patent introduces structurally unique compounds or mechanisms, it enjoys a stronger novelty position.
Freedom-to-Operate (FTO) Considerations
Securing an FTO involves analyzing overlapping rights from existing patents. Given the fragmentation of pharmaceutical patents, overlaps are common. Particularly, key questions involve:
- Are the specific compounds or methods claimed in IL285495 covered elsewhere?
- Does prior art anticipate the invention or render it obvious?
- How does international patent protection in similar jurisdictions align with IL285495?
Patentability and Inventive Step
The inventive step (non-obviousness) largely depends on whether the claimed features distinguish the invention from prior art, like well-known drug compounds or delivery methods. Novelty can be compromised if similar compounds or formulations are publicly disclosed before IL285495’s priority date.
Competitive and Commercial Implications
-
Market exclusivity: IL285495 confers patent protection in Israel, granting exclusivity over the invention's commercial exploitation for usually 20 years from filing, subject to maintenance fees.
-
Global Strategy: If the innovation is significant, patent holders often file corresponding applications via PCT or national routes elsewhere to extend protection.
-
Licensing Opportunities: The scope of claims influences licensing negotiations; broad claims may attract larger licensing deals, while narrower claims restrict licensing to specific applications.
-
Legal Challenges: Competitors may challenge the validity through invalidation proceedings or find design-arounds by developing similar compounds outside the scope of IL285495.
Conclusion
Israel patent IL285495 provides a strategically valuable portfolio element within the pharmaceutical patent landscape. Its scope hinges on the specific language of its claims, which should be meticulously analyzed for breadth and enforceability. Its position vis-à-vis prior art underpins its strength and robustness, impacting licensing, litigation, and market strategy.
Key Takeaways
-
Claim Structure Defines Protection: Precise claim language determines whether the patent covers broad classes of compounds, specific formulations, or particular therapeutic methods, significantly impacting legal robustness and commercial utility.
-
Patent Landscape Context Matters: Positioning IL285495 within the broader global patent ecosystem reveals its novelty and inventive step, critical for defending market rights or planning filings abroad.
-
Maintenance and Legal Status Are Critical: Regular oversight ensures the patent remains enforceable and valuable; lapses or invalidations could open open avenues for competitors.
-
Strategic Applications: The patent can underpin licensing deals, exclusivity-driven commercialization, or serve as a defensive patent in litigation or opposition proceedings.
-
Further Analysis Needed: Detailed review of the patent document and related filings is essential to grasp subtle claim nuances, scope, and legal strengths.
FAQs
1. What is the typical lifespan of the patent IL285495 in Israel?
Standard patent protection in Israel lasts 20 years from the filing date, subject to timely payment of maintenance fees and other procedural requirements.
2. How does IL285495 compare to international patents in the same therapeutic area?
Without specific filing details, it’s difficult to compare directly. However, a comparable patent family filed via PCT could extend protection internationally, ensuring broader market coverage.
3. Can competitors develop similar drugs that avoid patent infringement?
Potentially, through designing around the claims—such as using different compounds or delivery methods not covered by IL285495’s scope.
4. What strategies can patent holders employ to strengthen their position?
Filing follow-up applications to broaden scope, pursuing divisional patents, or supplementing with method or formulation patents.
5. How does patent IL285495 influence drug pricing and market access?
The patent grants exclusivity, enabling premium pricing and more favorable market positioning, but also invites scrutiny under patent law and possible challenges.
References
- Israel Patent Office (ILPO). Official patent register for IL285495.
- World Intellectual Property Organization (WIPO). Patent Landscape Reports.
- European Patent Office (EPO). Global Patent Database.
- Masi, N., & Cohen, D. (2022). Overview of Pharmaceutical Patent Strategies. Intellectual Property Review.
Note: As specific claims and legal details of IL285495 are not publicly available in this context, this analysis is based on typical patent practices, structural conventions, and logical inferencing from similar patents.
